DGAP-Media / 2019-12-12 / 12:50
*Aladdin Healthcare Technologies SE Announces
it has co-published a scientific paper on AI to target Ageing*
_(BERLIN, Germany and LONDON, England) 12 December 2019,_ Aladdin Healthcare
Technologies SE ("Aladdin"), a leading developer of next generation
breakthroughs in age-related disease accelerated by the integration of
leading science and AI today announced it has co-published a scientific
paper, in the 'Mechanisms of Ageing and Development' journal within Science
Direct by Elsevier.
The paper titled, 'The NAD+-mitophagy axis in healthy longevity and in
artificial intelligence-based clinical applications', delves into the
concept that NAD+ could hold the key to early diagnosis and delay of
neurodegenerative diseases. The paper focuses on 3 key points:
- Summarizing the importance of NAD+ and mitophagy in healthy longevity.
- Proposing an NAD+-mitophagy axis in health and disease, especially in
neurodegenerative diseases.
- Discuss the importance and how to use artificial intelligence (AI) in the
NAD+-mitophagy axis-based mechanistic studies, drug development.
Advances in our understanding of the molecular and cellular roles of NAD+ in
mitophagy will lead to novel approaches for facilitating healthy
mitochondrial homoeostasis that may serve as a promising therapeutic
strategy to counter ageing-associated pathologies and/or accelerated ageing.
The paper shows that by collaborating with academic and medical partners
Aladdin is changing the approach to early diagnosis of age-related disease
using our AI capability. This forms the foundation for innovation into new
products within this market.
Please follow this link to access the full paper:
https://www.sciencedirect.com/science/article/abs/pii/S004763741930199X [1]
Wade Menpes-Smith (Chairman)
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin
Healthcare Technologies Ltd.) is a leading developer of AI healthcare
diagnostics and drug discovery applications that can accelerate both early
stage disease diagnosis and the end-to-end drug discovery process. Aladdin
targets aged related disease including a significant focus on Alzheimer's
disease. Aladdin accomplishes this by collaborating with numerous partners
within the global healthcare ecosystem to confidentially and securely gather
targeted data including, genome, tabular, MRI, PET, cognition and other
lifestyle data. These datasets are then analysed by our award-winning AI
team and used to develop proprietary AI tools that can assist healthcare
professionals to more accurately and efficiently diagnose aged related
diseases. This new diagnostic process will save significant time and costs
for healthcare professionals. Additionally, our AI drug discovery platform
will be used to by pharmaceutical Companies to speed up drug development,
clinical trials and predict outcomes more accurately.
End of Media Release
Issuer: Aladdin Healthcare Technologies SE
Key word(s): Health
2019-12-12 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Germany
Phone: 030 700140449
E-mail: info@aladdinid.com
Internet: www.aladdinid.com
ISIN: DE000A12ULL2
WKN: A12ULL
Listed: Regulated Market in Dusseldorf
EQS News ID: 934627
End of News DGAP Media
934627 2019-12-12
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=2dc8dad5d58dce2549a78059321a85d9&application_id=934627&site_id=vwd&application_name=news
(END) Dow Jones Newswires
December 12, 2019 06:50 ET (11:50 GMT)
© 2019 Dow Jones News
